
Newly found mechanism can supercharge the immune system against cancers
New research has uncovered a novel mechanism that may help explain why some people with cancer respond remarkably well to immunotherapy while others don’t.

New research has uncovered a novel mechanism that may help explain why some people with cancer respond remarkably well to immunotherapy while others don’t.

University of North Carolina Lineberger Comprehensive Cancer Center researchers have developed a “two-in-one” molecule that can simultaneously turn off two notoriously difficult-to-target cancer-related genes, KRAS and MYC, as well as directly deliver drugs to tumors that express these genes. This advance holds special promise for treating cancers that have been historically challenging to treat.

https://medtechspectrum.com/news/40/24634/mirus-secures-ntap-approval-from-cms-for-breakthrough-europa-cervical-spine-system.html

SHENZHEN, China, Aug. 4, 2025 /PRNewswire/ — Pulsecare Medical, a pioneer in cardiovascular intervention technologies, announced that its innovative NxPFA™ nanosecond pulsed field ablation (ns-PFA) systemhas received marketing approval from China’s National Medical Products Administration (NMPA). As the world’s first third-generation ns-PFA system utilizing high-voltage nanosecond pulses for pulmonary vein isolation (PVI) in atrial fibrillation (AF) treatment, this breakthrough marks the dawn of the PFA 3.0 era and represents the innovative capabilities of Pulsecare Medical in cardiovascular multimodal therapy.

Stereotaxis (NYSE:STXS) announced today that it received FDA 510(k) clearance for its Magic Sweep navigation catheter.

Getinge announced today that European regulatory authorities reinstated the CE mark for its Cardiosave intra-aortic balloon pump.

In a study published in Advanced Materials, a research team developed an innovative bacterial cellulose (BC)-based hemostatic dressing that enables rapid and sustained bleeding control.

By understanding differences in how people’s brains are wired, clinicians may be able to predict who would benefit from a self-guided anxiety care app, according to a new analysis from a clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

Carlsmed (Nasdaq:CARL) today announced new technology add-on payment (NTAP) reimbursement for its spine implant technology.

Biomedical and genetic engineers at Duke University and the Albert Einstein College of Medicine have developed a technique that naturally increases the presence of a light-sensitive molecule throughout the body.